Grants and Contracts Details
| Status | Finished |
|---|---|
| Effective start/end date | 3/1/22 → 7/15/24 |
Funding
- Merck Sharp & Dohme Corporation: $24,658.00
A Phase 3, Multicenter, Randomized, Partially Blinded, Palivizumab- Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of MK-1654 in Infants and Children at Increased Risk for Severe RSV Disease
- Wurth, Mark (PI)
- Ballard, Hubert (CoI)